Ras Mutant Tumour Status
Contraindicated
Database
No EGFR-blockade benefit if downstream RAS mutated
Confirm RAS wild-type before use
Source: Kimi deep-research + Cla
Drug reference
Panitumumab
Anti-EGFR monoclonal antibody (fully human IgG2) · Antineoplastic
START
6 mg/kg IV every 14 days (RAS wild-type only)
TYPICAL MAX
6 mg/kg every 2 weeks
STOP IF
Severe skin toxicity, ILD, or grade 3–4 infusion reaction
WATCH
RAS status (before start), Mg/Ca/K, skin, pulmonary symptoms
CDSCO approvedSchedule HATC L01FE02
KDIGO 2024 + manufacturer label
- ONSET
- 6min · infusion start
- PEAK
- 1h · end infusion
- t½
- 1.1w · t½ ~7.5 d
- DURATION
- 2w · q2w interval
EXCRETION
Proteolytic catabolism; not excreted intact
route + CYP
INTERACTIONS
11 major
incl. contraindicated
PREGNANCY
Can cause fetal harm — avoid; contraception during and 2 months after.
FDA category + note
Top interactionssee all 12 →
- Ras Mutant Tumour StatusContraindicatedDatabaseKimi deep-research + Cla
- Aminolevulinic AcidSevereDatabaseDDInter
- AmiodaroneSevereDatabaseDDInter
- Arsenic TrioxideSevereDatabaseDDInter
Mechanism
Fully human IgG2 monoclonal antibody that binds the epidermal growth factor receptor (EGFR), blocking ligand binding and downstream proliferative/survival signalling in EGFR-expressing, RAS wild-type tumours.
Indications
Metastatic colorectal cancer — RAS wild-type (monotherapy or with chemotherapy)
Dosing
- Adult
- 6 mg/kg IV every 14 days (60-min infusion; longer for doses >1000 mg).
- Pediatric
- Not established.
- Renal adjustment
- No dose adjustment.
- Hepatic adjustment
- No specific adjustment (not studied in significant impairment).
- Geriatric
- No dose adjustment.
- Max dose
- 6 mg/kg every 2 weeks
Pharmacokinetics
Onset
Tumour response over weeks
Peak effect
End of infusion (serum)
Duration
~2-week dosing interval
Half-life
~7.5 days
Bioavailability
IV 100%
Protein binding
Not applicable (antibody)
Metabolism
Proteolytic catabolism
Excretion
Catabolised (not renally/hepatically excreted intact)
Contraindications
- RAS-mutant colorectal cancer (lack of benefit, possible harm)
- Severe hypersensitivity
- Caution: interstitial lung disease
Side effects
Common
Acneiform skin rashParonychiaHypomagnesaemiaDiarrhoeaFatigueHypocalcaemia
Serious
- Severe dermatologic toxicity / infection
- Severe infusion reactions
- Pulmonary fibrosis/interstitial lung disease
- Severe electrolyte depletion (Mg/Ca/K)
- Keratitis
Pregnancy & lactation
Pregnancy
Can cause fetal harm — avoid; contraception during and 2 months after.
Lactation
Avoid breastfeeding during and 2 months after therapy.
Drug interactions
Aminolevulinic Acid
Severe
Database
Clinical effect not specified
Source: DDInter
Amiodarone
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Arsenic Trioxide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Bevacizumab
Severe
Database
Antagonistic/added toxicity (PACCE)
Do not combine
Source: Kimi deep-research + Cla
Dofetilide
Severe
Database
Clinical effect not specified
Source: DDInter
Dronedarone
Severe
Database
Clinical effect not specified
Source: DDInter
Droperidol
Severe
Database
Clinical effect not specified
Source: DDInter
Levacetylmethadol
Severe
Database
Clinical effect not specified
Source: DDInter
Pimozide
Severe
Database
Clinical effect not specified
Source: DDInter
Ziprasidone
Severe
Database
Clinical effect not specified
Source: DDInter
Irinotecan
Moderate
Database
Additive toxicity / regimen-dependent outcomes
Use only validated regimens; avoid panitumumab+bevacizumab
Source: Kimi deep-research + Cla
Related guidelines
Ask House about Panitumumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, BNF·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20